AG˹ٷ

STOCK TITAN

[Form 4] Zeta Global Holdings Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Sight Sciences, Inc. (SGHT) filed a Form 144, providing notice of a proposed sale of restricted securities by an affiliate. The filing covers the planned disposition of 9,160 common shares, valued at approximately $38,235.67 based on prevailing market prices. The shares, which vested as restricted-stock compensation on 06/30/2025, are slated to be sold through Fidelity Brokerage Services on or about 07/03/2025 on NASDAQ.

With 51.7 million shares outstanding, the contemplated sale represents less than 0.02 % of total shares and therefore is unlikely to have a material impact on the float or trading dynamics. The filer reported no other insider sales in the past three months. While Form 144 sales signal insider liquidity activity, the modest size and compensation-related origin suggest routine portfolio management rather than a directional view on the company’s fundamentals.

Sight Sciences, Inc. (SGHT) ha presentato un Modulo 144, notificando una proposta di vendita di titoli soggetti a restrizioni da parte di un affiliato. La comunicazione riguarda la prevista cessione di 9.160 azioni ordinarie, valutate approssimativamente 38.235,67 $ in base ai prezzi di mercato correnti. Le azioni, maturate come compenso in azioni vincolate il 30/06/2025, saranno vendute tramite Fidelity Brokerage Services intorno al 03/07/2025 sul mercato NASDAQ.

Con 51,7 milioni di azioni in circolazione, la vendita prevista rappresenta meno dello 0,02% del totale, quindi è improbabile che abbia un impatto significativo sul flottante o sulle dinamiche di trading. Il dichiarante ha riportato nessun'altra vendita da parte di insider negli ultimi tre mesi. Sebbene le vendite tramite Modulo 144 indichino attività di liquidità da parte di insider, la dimensione contenuta e l’origine legata a compensi suggeriscono una gestione ordinaria del portafoglio piuttosto che una posizione direzionale sui fondamentali dell’azienda.

Sight Sciences, Inc. (SGHT) presentó un Formulario 144, notificando una venta propuesta de valores restringidos por parte de un afiliado. La presentación cubre la disposición planificada de 9,160 acciones comunes, valoradas aproximadamente en $38,235.67 según los precios de mercado vigentes. Las acciones, que se consolidaron como compensación en acciones restringidas el 30/06/2025, están programadas para ser vendidas a través de Fidelity Brokerage Services alrededor del 03/07/2025 en NASDAQ.

Con 51.7 millones de acciones en circulación, la venta contemplada representa menos del 0.02% del total, por lo que es poco probable que tenga un impacto significativo en el flotante o en la dinámica de negociación. El declarante reportó ninguna otra venta por parte de insiders en los últimos tres meses. Aunque las ventas bajo el Formulario 144 señalan actividad de liquidez interna, el tamaño modesto y el origen relacionado con la compensación sugieren una gestión rutinaria de cartera en lugar de una opinión direccional sobre los fundamentos de la empresa.

Sight Sciences, Inc. (SGHT)� Form 144� 제출하여 계열사의 제한� 증권 매각 예정 사실� 통지했습니다. 제출 내용은 9,160� 보통�� 처분 계획� 포함하며, 현재 시장 가격을 기준으로 � 38,235.67달러� 해당합니�. � 주식들은 2025� 6� 30�� 제한 주식 보상으로 취득되었으며, 2025� 7� 3일경 Fidelity Brokerage Services� 통해 NASDAQ에서 매각� 예정입니�.

5,170� �가 발행� 상황에서 이번 매각은 전체 주식� 0.02% 미만� 해당하므� 유통 주식 수나 거래 동향� � 영향� 미칠 가능성은 낮습니다. 제출자는 지� 3개월� 다른 내부� 매도 기록� 없음� 보고했습니다. Form 144 매도� 내부자의 유동� 활동� 나타내지�, 규모가 작고 보상� 관련된 주식임을 고려� � 회사� 기본적인 전망� 대� 방향성보다는 일상적인 포트폴리� 관리로 해석됩니�.

Sight Sciences, Inc. (SGHT) a déposé un Formulaire 144, annonçant une vente proposée de titres restreints par un affilié. Le dépôt concerne la cession prévue de 9 160 actions ordinaires, d'une valeur d'environ 38 235,67 $ selon les prix du marché en vigueur. Ces actions, attribuées en tant que rémunération en actions restreintes le 30/06/2025, devraient être vendues via Fidelity Brokerage Services aux alentours du 03/07/2025 sur le NASDAQ.

Avec 51,7 millions d'actions en circulation, la vente envisagée représente moins de 0,02 % du total, ce qui rend peu probable un impact significatif sur le flottant ou la dynamique de négociation. Le déclarant a indiqué aucune autre vente d'initiés au cours des trois derniers mois. Bien que les ventes via le Formulaire 144 indiquent une activité de liquidité des initiés, la taille modeste et l'origine liée à une rémunération suggèrent une gestion de portefeuille de routine plutôt qu'une prise de position sur les fondamentaux de l'entreprise.

Sight Sciences, Inc. (SGHT) hat ein Formular 144 eingereicht und damit den geplanten Verkauf von eingeschränkten Wertpapieren durch einen verbundenen Dritten gemeldet. Die Einreichung betrifft die geplante Veräußerung von 9.160 Stammaktien, die nach aktuellem Marktpreis einen Wert von etwa 38.235,67 $ haben. Die Aktien, die am 30.06.2025 als eingeschränkte Aktienvergütung zugeteilt wurden, sollen etwa am 03.07.2025 über Fidelity Brokerage Services an der NASDAQ verkauft werden.

Bei 51,7 Millionen ausstehenden Aktien entspricht der geplante Verkauf weniger als 0,02 % des Gesamtbestands und wird daher voraussichtlich keine wesentlichen Auswirkungen auf den Streubesitz oder die Handelsdynamik haben. Der Melder gab an, in den letzten drei Monaten keine weiteren Insider-Verkäufe getätigt zu haben. Während Verkäufe über Formular 144 auf Insider-Liquiditätsaktivitäten hinweisen, deuten die geringe Größe und die kompensationsbedingte Herkunft auf eine routinemäßige Portfoliosteuerung hin und nicht auf eine richtungsweisende Einschätzung der Fundamentaldaten des Unternehmens.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider sale (9,160 shares, <0.02 %)—routine, immaterial for valuation.

The Form 144 signals an upcoming insider sale stemming from restricted-stock vesting. At roughly $38 k, the transaction is de-minimis relative to Sight Sciences� market capitalization and daily trading volume. No aggregation of prior sales was required, indicating limited ongoing insider selling pressure. Such routine liquidity events typically have negligible valuation impact but can be monitored for trend changes if additional filings emerge.

Sight Sciences, Inc. (SGHT) ha presentato un Modulo 144, notificando una proposta di vendita di titoli soggetti a restrizioni da parte di un affiliato. La comunicazione riguarda la prevista cessione di 9.160 azioni ordinarie, valutate approssimativamente 38.235,67 $ in base ai prezzi di mercato correnti. Le azioni, maturate come compenso in azioni vincolate il 30/06/2025, saranno vendute tramite Fidelity Brokerage Services intorno al 03/07/2025 sul mercato NASDAQ.

Con 51,7 milioni di azioni in circolazione, la vendita prevista rappresenta meno dello 0,02% del totale, quindi è improbabile che abbia un impatto significativo sul flottante o sulle dinamiche di trading. Il dichiarante ha riportato nessun'altra vendita da parte di insider negli ultimi tre mesi. Sebbene le vendite tramite Modulo 144 indichino attività di liquidità da parte di insider, la dimensione contenuta e l’origine legata a compensi suggeriscono una gestione ordinaria del portafoglio piuttosto che una posizione direzionale sui fondamentali dell’azienda.

Sight Sciences, Inc. (SGHT) presentó un Formulario 144, notificando una venta propuesta de valores restringidos por parte de un afiliado. La presentación cubre la disposición planificada de 9,160 acciones comunes, valoradas aproximadamente en $38,235.67 según los precios de mercado vigentes. Las acciones, que se consolidaron como compensación en acciones restringidas el 30/06/2025, están programadas para ser vendidas a través de Fidelity Brokerage Services alrededor del 03/07/2025 en NASDAQ.

Con 51.7 millones de acciones en circulación, la venta contemplada representa menos del 0.02% del total, por lo que es poco probable que tenga un impacto significativo en el flotante o en la dinámica de negociación. El declarante reportó ninguna otra venta por parte de insiders en los últimos tres meses. Aunque las ventas bajo el Formulario 144 señalan actividad de liquidez interna, el tamaño modesto y el origen relacionado con la compensación sugieren una gestión rutinaria de cartera en lugar de una opinión direccional sobre los fundamentos de la empresa.

Sight Sciences, Inc. (SGHT)� Form 144� 제출하여 계열사의 제한� 증권 매각 예정 사실� 통지했습니다. 제출 내용은 9,160� 보통�� 처분 계획� 포함하며, 현재 시장 가격을 기준으로 � 38,235.67달러� 해당합니�. � 주식들은 2025� 6� 30�� 제한 주식 보상으로 취득되었으며, 2025� 7� 3일경 Fidelity Brokerage Services� 통해 NASDAQ에서 매각� 예정입니�.

5,170� �가 발행� 상황에서 이번 매각은 전체 주식� 0.02% 미만� 해당하므� 유통 주식 수나 거래 동향� � 영향� 미칠 가능성은 낮습니다. 제출자는 지� 3개월� 다른 내부� 매도 기록� 없음� 보고했습니다. Form 144 매도� 내부자의 유동� 활동� 나타내지�, 규모가 작고 보상� 관련된 주식임을 고려� � 회사� 기본적인 전망� 대� 방향성보다는 일상적인 포트폴리� 관리로 해석됩니�.

Sight Sciences, Inc. (SGHT) a déposé un Formulaire 144, annonçant une vente proposée de titres restreints par un affilié. Le dépôt concerne la cession prévue de 9 160 actions ordinaires, d'une valeur d'environ 38 235,67 $ selon les prix du marché en vigueur. Ces actions, attribuées en tant que rémunération en actions restreintes le 30/06/2025, devraient être vendues via Fidelity Brokerage Services aux alentours du 03/07/2025 sur le NASDAQ.

Avec 51,7 millions d'actions en circulation, la vente envisagée représente moins de 0,02 % du total, ce qui rend peu probable un impact significatif sur le flottant ou la dynamique de négociation. Le déclarant a indiqué aucune autre vente d'initiés au cours des trois derniers mois. Bien que les ventes via le Formulaire 144 indiquent une activité de liquidité des initiés, la taille modeste et l'origine liée à une rémunération suggèrent une gestion de portefeuille de routine plutôt qu'une prise de position sur les fondamentaux de l'entreprise.

Sight Sciences, Inc. (SGHT) hat ein Formular 144 eingereicht und damit den geplanten Verkauf von eingeschränkten Wertpapieren durch einen verbundenen Dritten gemeldet. Die Einreichung betrifft die geplante Veräußerung von 9.160 Stammaktien, die nach aktuellem Marktpreis einen Wert von etwa 38.235,67 $ haben. Die Aktien, die am 30.06.2025 als eingeschränkte Aktienvergütung zugeteilt wurden, sollen etwa am 03.07.2025 über Fidelity Brokerage Services an der NASDAQ verkauft werden.

Bei 51,7 Millionen ausstehenden Aktien entspricht der geplante Verkauf weniger als 0,02 % des Gesamtbestands und wird daher voraussichtlich keine wesentlichen Auswirkungen auf den Streubesitz oder die Handelsdynamik haben. Der Melder gab an, in den letzten drei Monaten keine weiteren Insider-Verkäufe getätigt zu haben. Während Verkäufe über Formular 144 auf Insider-Liquiditätsaktivitäten hinweisen, deuten die geringe Größe und die kompensationsbedingte Herkunft auf eine routinemäßige Portfoliosteuerung hin und nicht auf eine richtungsweisende Einschätzung der Fundamentaldaten des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
NIEHAUS ROBERT H

(Last) (First) (Middle)
600 LEXINGTON AVENUE, 31ST FLOOR

(Street)
NEW YORK NY 10022

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zeta Global Holdings Corp. [ ZETA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/01/2025 A 9,907(1) A $0 318,465 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock, which vests in four equal installments on July 1, 2026, October 1, 2026, January 1, 2027, and April 1, 2027.
/s/ Robert Niehaus 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Sight Sciences (SGHT) shares are covered by this Form 144 filing?

9,160 common shares are proposed for sale.

What is the aggregate market value of the SGHT shares to be sold?

The filing lists an aggregate value of $38,235.67.

When is the approximate sale date for the SGHT shares?

The sale is expected on or about 07/03/2025.

What percentage of outstanding SGHT shares does the sale represent?

Less than 0.02 % of the 51,702,088 shares outstanding.

How were the shares acquired by the insider?

They vested as restricted-stock compensation on 06/30/2025.

Have there been other insider sales of SGHT stock in the last three months?

The Form 144 reports no other sales during the past three months.
Zeta Global Holdings Corp

NYSE:ZETA

ZETA Rankings

ZETA Latest News

ZETA Latest SEC Filings

ZETA Stock Data

3.33B
184.00M
10%
70.76%
11.31%
Software - Infrastructure
Services-prepackaged Software
United States
NEW YORK